Compared to the slowdown happening in the broader innovation economy, women's health is seeing more of a speed bump. We expect deal counts and dollars to accelerate with a greater realization of the unmet health needs of women, improvement in women’s health research and funding as the sector matures.

One reason for the lower valuations could be the lack of data collection on women’s health conditions. This is a roadblock when it comes to convincing investors there is a need, accurately estimating market size, receiving FDA approval, and getting reimbursement in unchartered waters. However, valuations could increase as investors are encouraged by efforts such as the White House Initiative on Women’s Health Research which aims to close the research gaps in the space.